Humanized mice (target-specific)

Well-established mouse lines that allow in vivo efficacy and safety assessment of biologics and other compounds.

Applications

These models are suitable to assess the efficacy of compounds targeting human proteins in fully immunocompetent mice. Moreover, they represent a powerful model system for studying how compounds modulate cell response and/or stroma cells in a physiological microenvironment.

General model features

  • Physiological expression of the human target(s)
  • Preservation of the target-ligand interaction
  • Fully functional mouse immune system
  • Lack of expression of the murine target gene, thus avoiding cross-reactivity

Discover our

Humanized mice (target-specific)

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

HSA/hFcRn

Double humanized HSA-hFcRn mouse model as a cutting-edge platform for preclinical development of HSA and FcRn-oriented therapeutics.

Mouse
HSA
PK/PD

HSA/hFcRn-Rag1-KO

This upgraded, immunocompromised Rag1-/- version of our HSA/hFcRn mouse model allows the assessment of compounds' half-life and anti-tumor efficacy in a human tumor model.

Mouse
HSA
PK/PD
Immunodeficient

hVISTA

The hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint VISTA in fully immunocompetent mice.

Mouse
ICP
VISTA
ICP (single-target)

hcGAS

The hcGAS mouse enables the in vivo assessment of agents and therapies targeting the cGAS–STING cytosolic DNA sensing pathway in fully immunocompetent mice.

Mouse
cGAS
cGAS-STING pathway

Pan hCD3

Pan hCD3 immunocompetent mice enable the efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

T-cell engager
CD3
Mouse

hSTING

The hSTING mouse enables the in vivo assessment of agents and therapies targeting  the human immune checkpoint STING in fully immunocompetent mice.

Mouse
STING
cGAS-STING pathway

hTFRC

The hTFRC mouse model enables in vivo efficacy assessment and profiling of compounds targeting the human cell shuttle TFRC in fully immunocompetent mice.

Mouse
TFRC
Cell shuttling

hCD3ε

hCD3ε immunocompetent mice enable the preclinical in vivo efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

T-cell engager
CD3
Mouse

hCD3ε/hCD28

hCD3ε  immunocompetent mice enable the efficacy assessment of T-cell engagers, to  study cancer cell recognition, immunosuppressant therapies, etc.

CD3
Mouse
CD28
T-cell engager

hPD-1

The hPD-1 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 in fully immunocompetent mice.

Mouse
PD-1
ICP
ICP (single-target)

hCTLA-4/hLAG3

The hCTLA-4/hLAG3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 and/or LAG3 in fully immunocompetent mice.

Mouse
ICP
CTLA-4
Lag3
ICP (multi-target)

hPD-1/hCTLA-4

The hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice.

Mouse
ICP
CTLA-4
PD-1
ICP (multi-target)

hGITR/hGITRL

The hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of agonist and antagonist antibodies targeting human immune checkpoint GITR and/or GITRL in fully immunocompetent mice.

Mouse
ICP
GITR
GITRL
ICP (multi-target)

hGITR/Foxp3

The hGITR/Foxp3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR. The red fluorescent protein regulated under the Foxp3 promoter allows you to efficiently monitor and sort Foxp3-expressing cells from different lymphocyte lineages and lymphoid organs.

Mouse
ICP
Reporter
GITR
Foxp3

hPD-1/hPD-L1

The hPD-1/hPD-L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice.

Mouse
ICP
PD-1
PD-L1
ICP (multi-target)

hPD-1/hTIM3

The hPD-1/hTIM3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or TIM3 in fully immunocompetent mice.

Mouse
ICP
PD-1
TIM3
ICP (multi-target)

hPD-1/hVISTA

The hPD-1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

Mouse
ICP
PD-1
VISTA
ICP (multi-target)

hPD-1/hLAG3

The hPD-1/hLAG3 mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice.

Mouse
ICP
PD-1
Lag3
ICP (multi-target)

hCD28

The hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.

Mouse
ICP
CD28
ICP (single-target)

hCD39

The hCD39 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD39 in fully immunocompetent mice.

Mouse
ICP
CD39
ICP (single-target)

hGITR

The hGITR mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR in fully immunocompetent mice.

Mouse
ICP
GITR
ICP (single-target)

hCTLA-4

The hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 in fully immunocompetent mice.

Mouse
ICP
CTLA-4
ICP (single-target)

hOX40

The hOX40 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint OX40 in fully immunocompetent mice.

Mouse
ICP
OX40
ICP (single-target)

hPD-1/hGITR/hGITRL

The hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

Mouse
ICP
PD-1
GITR
ICP (multi-target)

hCD4

The human CD4 mouse model allows in vivo efficacy and safety assessment of anti-human CD4 compounds.

Mouse
CD4
Inflammation

hIgE/hFcεR1

Use the hIgE/hFcεR1 mouse model to successfully screen for innovative therapeutics for allergy, asthma and other IgE-mediated diseases.

Mouse
Inflammation
IgE
FceR1

hTNF-α

The hTNF-α model provides new opportunities for assessment of anti-TNF therapies.

Mouse
Inflammation
TNF

Discover our customized models

Learn  more

Related resources and publications

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No results